267 related articles for article (PubMed ID: 35596182)
21. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
Musoro JZ; Coens C; Greimel E; King MT; Sprangers MAG; Nordin A; van Dorst EBL; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
Gynecol Oncol; 2020 Nov; 159(2):515-521. PubMed ID: 32972782
[TBL] [Abstract][Full Text] [Related]
22. Challenging the current norm: Does health related quality of life data from reference populations accurately reflect baseline values in breast cancer patients? An observational cohort study comparing EORTC QLQ-C30 scores between the general Swedish population and baseline scores in breast cancer patients.
Sjökvist O; Håkansson S; Pantiora E; Karakatsanis A
Eur J Surg Oncol; 2021 Dec; 47(12):2971-2977. PubMed ID: 34412955
[TBL] [Abstract][Full Text] [Related]
23. Danish population-based reference data for the EORTC QLQ-C30: associations with gender, age and morbidity.
Juul T; Petersen MA; Holzner B; Laurberg S; Christensen P; Grønvold M
Qual Life Res; 2014 Oct; 23(8):2183-93. PubMed ID: 24676897
[TBL] [Abstract][Full Text] [Related]
24. Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial.
Wallwiener M; Matthies L; Simoes E; Keilmann L; Hartkopf AD; Sokolov AN; Walter CB; Sickenberger N; Wallwiener S; Feisst M; Gass P; Fasching PA; Lux MP; Wallwiener D; Taran FA; Rom J; Schneeweiss A; Graf J; Brucker SY
J Med Internet Res; 2017 Sep; 19(9):e322. PubMed ID: 28912116
[TBL] [Abstract][Full Text] [Related]
25. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study.
Schmid P; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Mejia JA; Zhou X; Haiderali A; Nguyen AM; Cortes J; Winer EP
Eur J Cancer; 2023 Dec; 195():113393. PubMed ID: 37976633
[TBL] [Abstract][Full Text] [Related]
26. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
Robson M; Ruddy KJ; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Li W; Tung N; Armstrong A; Delaloge S; Bannister W; Goessl C; Degboe A; Hettle R; Conte P
Eur J Cancer; 2019 Oct; 120():20-30. PubMed ID: 31446213
[TBL] [Abstract][Full Text] [Related]
27. Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial).
Ramage JK; Punia P; Faluyi O; Frilling A; Meyer T; Saharan R; Valle JW
Neuroendocrinology; 2019; 108(4):317-327. PubMed ID: 30699423
[TBL] [Abstract][Full Text] [Related]
28. EORTC QLQ-C30 normative data for the United Kingdom: Results of a cross-sectional survey of the general population.
Young T; Velikova G; Liegl G; Rose M; Nolte S;
Eur J Cancer; 2024 Jun; 204():113927. PubMed ID: 38429166
[TBL] [Abstract][Full Text] [Related]
29. Using reference data on quality of life--the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3).
Hjermstad MJ; Fayers PM; Bjordal K; Kaasa S
Eur J Cancer; 1998 Aug; 34(9):1381-9. PubMed ID: 9849421
[TBL] [Abstract][Full Text] [Related]
30. General Spanish population normative data analysis for the EORTC QLQ-C30 by sex, age, and health condition.
Arraras JI; Nolte S; Liegl G; Rose M; Manterola A; Illarramendi JJ; Zarandona U; Rico M; Teiejria L; Asin G; Hernandez I; Barrado M; Vera R; Efficace F; Giesinger JM;
Health Qual Life Outcomes; 2021 Aug; 19(1):208. PubMed ID: 34461909
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma.
Reni M; Braverman J; Hendifar A; Li CP; Macarulla T; Oh DY; Riess H; Tempero M; Lu B; Marcus J; Joshi N; Botteman M; Dueck AC
Ann Surg Oncol; 2021 Nov; 28(12):7545-7554. PubMed ID: 33813673
[TBL] [Abstract][Full Text] [Related]
32. The relationship of changes in EORTC QLQ-C30 scores to ratings on the Subjective Significance Questionnaire in men with localized prostate cancer.
Rodrigues G; Bezjak A; Osoba D; Catton P; Tsuji D; Taylor D; Warde P
Qual Life Res; 2004 Sep; 13(7):1235-46. PubMed ID: 15473502
[TBL] [Abstract][Full Text] [Related]
33. The assessment of health-related quality of life and related factors in Chinese elderly patients undergoing chemotherapy for advanced cancer: a cross-sectional study.
Li Q; Lin Y; Qiu Y; Gao B; Xu Y
Eur J Oncol Nurs; 2014 Aug; 18(4):425-35. PubMed ID: 24721179
[TBL] [Abstract][Full Text] [Related]
34. Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.
Quidde J; Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Lange T; Dietrich G; Stoehlmacher J; Reinacher A; Tannapfel A; Trarbach T; Marschner N; Schmoll HJ; Hinke A; Al-Batran SE; Arnold D
Ann Oncol; 2016 Dec; 27(12):2203-2210. PubMed ID: 27753609
[TBL] [Abstract][Full Text] [Related]
35. Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629.
Hughes BGM; Mendoza RG; Basset-Seguin N; Vornicova O; Schachter J; Joshi A; Meyer N; Grange F; Piulats JM; Bauman JR; Chirovsky D; Zhang P; Gumuscu B; Swaby RF; Grob JJ
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1777-1790. PubMed ID: 34558040
[TBL] [Abstract][Full Text] [Related]
36. Quality of life after low-dose rate-brachytherapy for prostate carcinoma - long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series.
Buergy D; Schneiberg V; Schaefer J; Welzel G; Trojan L; Bolenz C; Wenz F
Health Qual Life Outcomes; 2018 Jan; 16(1):21. PubMed ID: 29357874
[TBL] [Abstract][Full Text] [Related]
37. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
38. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-c30): validation of English version in Singapore.
Luo N; Fones CS; Lim SE; Xie F; Thumboo J; Li SC
Qual Life Res; 2005 May; 14(4):1181-6. PubMed ID: 16041912
[TBL] [Abstract][Full Text] [Related]
39. Updated EORTC QLQ-C30 general population norm data for Germany.
Nolte S; Waldmann A; Liegl G; Petersen MA; Groenvold M; Rose M;
Eur J Cancer; 2020 Sep; 137():161-170. PubMed ID: 32777715
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
